Holen Sie sich die Stockscreener-App
38.23
0.23%
-0.09
Vorhandelsmarkt:
38.49
0.26
+0.68%
Schlusskurs vom Vortag:
$38.32
Offen:
$38.195
24-Stunden-Volumen:
1.17M
Relative Volume:
0.80
Marktkapitalisierung:
$2.65B
Einnahmen:
$18.09M
Nettoeinkommen (Verlust:
$-208.87M
KGV:
-10.88
EPS:
-3.5125
Netto-Cashflow:
$-178.15M
1W Leistung:
-13.11%
1M Leistung:
-25.11%
6M Leistung:
+133.68%
1J Leistung:
-27.39%
1-Tages-Spanne:
$37.62
$39.12
1-Wochen-Bereich:
$36.82
$45.80
52-Wochen-Spanne:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Firmenname
Uniqure Nv
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
38.23 | 2.65B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Mizuho | Neutral → Outperform |
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure Nv Aktie (QURE) Neueste Nachrichten
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
QURE Stock Price, Quote & Chart - ChartMill
uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS
Why is uniQure stock sliding today? - Investing.com
Why is uniQure stock sliding today? By Investing.com - Investing.com Australia
uniQure stock falls 5.57 percent as cash reaches USD 810.3 million - AD HOC NEWS
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure stock eyes key AMT-130 update as Huntington’s gene therapy advances - ad-hoc-news.de
uniQure stock holds recent gains as Huntington’s gene therapy filing reshapes outlook - AD HOC NEWS
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews
What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application? - Yahoo Finance
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance
uniQure Submits BLA and MAA for AMT-130 Gene Therapy in Huntington's Disease - BioPharm International
QURE Submits Application for Gene Therapy for Huntington's Disease - The Globe and Mail
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - Moomoo
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $75 - moomoo.com
QURE Reinstated by William Blair -- Rating Set to Outperform - GuruFocus
Why is Uniqure NV stock gaining today? - Investing.com
uniQure seeks FDA accelerated nod for gene therapy (QURE) - Seeking Alpha
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says - Benzinga
Why is Uniqure NV stock gaining today? By Investing.com - Investing.com India
uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
QURE Looks 505.1% Overvalued on GF Value™ - GuruFocus
UniQure Submits BLA for AMT-130 in Huntington's Disease - marketscreener.com
uniQure submits BLA to FDA and MAA to MHRA for AMT-130 in Huntington’s disease - tradingview.com
uniQure Announces Submission of Biologics License - GlobeNewswire
Uniqure (QURE) Financials FY2025: Revenue $16.1M, Net Loss $199.0M | Income Statement & Balance Sheet - Stock Titan
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Yahoo Finance
Price to sales forward of uniQure N.V. – NASDAQ:QURE - TradingView
RTW INVESTMENTS, LP Buys uniQure NV (QURE) -- Shares Look 531% O - GuruFocus
uniQure N.V. - Reuters
Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE - MarketBeat
uniQure (QURE) Advances 3.31% as Gene Therapy Optimism ReturnsDividend Growth Stocks - Vinanet
Responsive Playbooks and the QURE Inflection - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71 - Moomoo
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
Finanzdaten der Uniqure Nv-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):